Sacubitril/Valsartan: potential treatment for paediatric heart failure

Bibhuti B. Das; Frank Scholl; Breanna Vandale; Maryanne Chrisant

doi:10.1017/S1047951118001014

Sacubitril/Valsartan: potential treatment for paediatric heart failure

Bibhuti B. Das, Frank Scholl, Breanna Vandale, Maryanne Chrisant

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure trial has demonstrated that Sacubitril/Valsartan is superior to Enalapril in reducing the risks of both sudden cardiac death and death from worsening heart failure. This novel combination, Sacubitril/Valsartan, is also shown to reduce the risk of hospitalisation and progression of heart failure in adults. However, the benefit of Sacubitril/Valsartan in paediatric heart failure patients is unknown. In this review, we discuss the similarities and differences in pathophysiology of heart failure in children versus adults, and the potential role of Sacubitril/Valsartan in paediatric heart failure patients.

Original language	English (US)
Pages (from-to)	1-5
Number of pages	5
Journal	Cardiology in the Young
DOIs	https://doi.org/10.1017/S1047951118001014
State	Accepted/In press - Jul 6 2018

Keywords

angiotensin receptor blocker
neprilysin inhibitor
Paediatric heart failure

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Cardiology and Cardiovascular Medicine

Access to Document

10.1017/S1047951118001014

Cite this

@article{9991f5bcc4cf42469826e1aedf6a6822,

title = "Sacubitril/Valsartan: potential treatment for paediatric heart failure",

abstract = "The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure trial has demonstrated that Sacubitril/Valsartan is superior to Enalapril in reducing the risks of both sudden cardiac death and death from worsening heart failure. This novel combination, Sacubitril/Valsartan, is also shown to reduce the risk of hospitalisation and progression of heart failure in adults. However, the benefit of Sacubitril/Valsartan in paediatric heart failure patients is unknown. In this review, we discuss the similarities and differences in pathophysiology of heart failure in children versus adults, and the potential role of Sacubitril/Valsartan in paediatric heart failure patients.",

keywords = "angiotensin receptor blocker, neprilysin inhibitor, Paediatric heart failure",

author = "Das, {Bibhuti B.} and Frank Scholl and Breanna Vandale and Maryanne Chrisant",

year = "2018",

month = jul,

day = "6",

doi = "10.1017/S1047951118001014",

language = "English (US)",

pages = "1--5",

journal = "Cardiology in the Young",

issn = "1047-9511",

publisher = "Cambridge University Press",

}

TY - JOUR

T1 - Sacubitril/Valsartan

T2 - potential treatment for paediatric heart failure

AU - Das, Bibhuti B.

AU - Scholl, Frank

AU - Vandale, Breanna

AU - Chrisant, Maryanne

PY - 2018/7/6

Y1 - 2018/7/6

N2 - The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure trial has demonstrated that Sacubitril/Valsartan is superior to Enalapril in reducing the risks of both sudden cardiac death and death from worsening heart failure. This novel combination, Sacubitril/Valsartan, is also shown to reduce the risk of hospitalisation and progression of heart failure in adults. However, the benefit of Sacubitril/Valsartan in paediatric heart failure patients is unknown. In this review, we discuss the similarities and differences in pathophysiology of heart failure in children versus adults, and the potential role of Sacubitril/Valsartan in paediatric heart failure patients.

AB - The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure trial has demonstrated that Sacubitril/Valsartan is superior to Enalapril in reducing the risks of both sudden cardiac death and death from worsening heart failure. This novel combination, Sacubitril/Valsartan, is also shown to reduce the risk of hospitalisation and progression of heart failure in adults. However, the benefit of Sacubitril/Valsartan in paediatric heart failure patients is unknown. In this review, we discuss the similarities and differences in pathophysiology of heart failure in children versus adults, and the potential role of Sacubitril/Valsartan in paediatric heart failure patients.

KW - angiotensin receptor blocker

KW - neprilysin inhibitor

KW - Paediatric heart failure

UR - http://www.scopus.com/inward/record.url?scp=85049560897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049560897&partnerID=8YFLogxK

U2 - 10.1017/S1047951118001014

DO - 10.1017/S1047951118001014

M3 - Article

C2 - 29979147

AN - SCOPUS:85049560897

SN - 1047-9511

SP - 1

EP - 5

JO - Cardiology in the Young

JF - Cardiology in the Young

ER -

Sacubitril/Valsartan: potential treatment for paediatric heart failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this